Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized adults with COVID-19: a population-based, retrospective cohort study
Among outpatients aged ≥60 years with COVID-19 in an Omicron-dominated era, treatment with nirmatrelvir-ritonavir was associated with a lower risk of hospitalization and all-cause death within 28 days, albeit with wide CIs and high numbers needed to treat. This finding was not observed in molnupiravir users and younger nirmatrelvir-ritonavir users.
Authors
- Arschang Valipour (ORCID: https://orcid.org/0000-0001-6574-1721)
- Anselm Jorda (ORCID: https://orcid.org/0000-0001-5500-5878)
- Alexander Zoufaly (ORCID: https://orcid.org/0000-0002-3329-7088)
- Robin Ristl (ORCID: https://orcid.org/0000-0002-4163-9236)
- Marton Széll
- Bernhard Riedl
- Hatice Eser
- Markus Zeitlinger (ORCID: https://orcid.org/0000-0002-1873-3953)
- Ursula Karnthaler
- Christoph Wenisch
- Heinz Burgmann (ORCID: https://orcid.org/0000-0002-2114-0999)
- Florian Götzinger (ORCID: https://orcid.org/0000-0002-1546-8111)
- Bernd Jilma (ORCID: https://orcid.org/0000-0001-5652-7977)
- Florian Thalhammer (ORCID: https://orcid.org/0000-0001-6523-8229)
- Doris Haider
- Dominik Ensle
- Florentin Glötzl
Institutions
- Vienna University of Economics and Business (AT)
- Donauspital (AT)
- Kaiser-Franz-Josef-Spital (AT)
- Karl Landsteiner Society (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Clinical Microbiology and Infection
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1016/j.cmi.2024.10.026
- Citations
- 12
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.67
Funders
- Novavax